jRCT1031250596招募中不适用
A Randomized Controlled Trial Evaluating Concentration-Volume Effects of Local Anesthetic Administration in the Lateral Pterygoid Muscle (OPTIMAL Study: Outcome comparison of Pterygoid muscle Targeted Injection with Modified Anesthetic Loading) (OPTIMAL Study)
未提供0 个研究点目标入组 60 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Adults aged 18 years or older
- •Scheduled for impacted wisdom tooth extraction under general anesthesia with ASA-PS classification 1 or 2
- •Able to provide written informed consent and communicate in Japanese
排除标准
- •History of allergy to amide-type local anesthetics
- •Pregnant or breastfeeding
- •Severe hepatic impairment (Child-Pugh class B or higher)
- •Severe renal impairment (eGFR less than 30mL/min/1.73m2)
- •Anticoagulation therapy with PT-INR greater than 1.5
- •Under treatment for chronic pain
- •History of severe psychiatric disorders
- •Limited mouth opening (maximum opening less than 25mm)
- •Refusal to participate in the study
研究者
相似试验
尚未招募
2 期
Evaluate The Efficacy Of Panchmool Siddha Milk As Pathya In Chronic RhinitisChronic rhinitis. Ayurveda Condition: NASAROGAH,CTRI/2025/04/084118National Institute Of Ayurveda Jaipur60
招募中
1 期
A phase 1, double-blind, placebo-controlled, randomized, single ascending dose and multiple ascending dose study to assess the safety, tolerability, and pharmacokinetics of GHF-201 in healthy adult volunteers2024-519813-74-00CCDRD Cooperative Clinical Drug Research and Development AG, GHF-Golden Heart Flower Ltd.32
招募中
4 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fasting condition.plaque psoriasis2025-523838-13-00Sun Pharmaceutical Industries Limited40
已完成
4 期
An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.2024-512770-10-00Sun Pharmaceutical Industries Limited50
招募中
4 期
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fed condition.ulcerative colitis2025-520618-76-00Sun Pharmaceutical Industries Limited112